BRCA1 and BRCA2 PVs confer increased risks of prostate, pancreatic, and ovarian cancers [44], while moderate-to-high risks of pancreatic (OR 4.21), prostate (OR 2.58), and gastric (OR 2.97) cancers were estimated for ATM-variant carriers [24]. Here, ATM is linked to ovarian carcinoma.